Updated November 10, 2026
Regulatory links last verified November 10, 2026.
Summary
Testosterone replacement therapy in Europe is available as intramuscular (IM) testosterone esters, transdermal gels and oral testosterone undecanoate. Implants, transdermal patches and buccal tablets have also been authorized in the past. These formulations differ in absorption, dosing interval, dose flexibility, tolerability and the rate at which exposure declines after the last dose.
Testosterone medicines in the European Union (EU) have been authorized through national procedures (EMA n.d.-b). For this reason, “EMA-approved testosterone” is an inaccurate description of these products. The European Medicines Agency (EMA) coordinates EU-wide safety reviews, whereas national authorities hold the product-specific authorization records. Intrinsa, a testosterone patch for women, received a central EU authorization in 2006 and was withdrawn in 2012 (EMA n.d.-a).
This review describes the main formulation families and the named preparations documented in European regulatory sources. It separates current national authorizations from historical records and withdrawn products.
Scope: Preparations in the EU and the European Economic Area (EEA), with UK information identified where relevant. This is a formulation-level review with product examples, not a complete register of every national license, parallel import and pack size. Authorization in a single country does not mean that a product is available throughout Europe. Nandrolone, methyltestosterone and other synthetic androgens are outside the scope.
| Formulation | Usual interval | Main advantage | Main limitation |
|---|---|---|---|
| IM testosterone undecanoate | Every 10 to 14 weeks after initiation (Nebido) | Fewest administrations | Exposure declines slowly after a dose; pulmonary oil microembolism |
| IM testosterone enanthate | Product-specific | Long clinical experience; dose and interval can be adjusted | Peak and trough fluctuation |
| IM testosterone cypionate | Every 2 to 4 weeks (Testex) | Adjustable schedule | Peak and trough fluctuation |
| IM mixed esters | Product-specific | No daily administration | Fluctuation persists despite mixed release rates |
| Transdermal gel | Daily | Prompt dose adjustment; noninvasive | Secondary transfer to others; daily adherence |
| Oral testosterone undecanoate | Twice daily with meals | No injection or skin application | Absorption depends on food intake |
| Patches, buccal tablets, implants | Variable | Mainly of historical relevance in Europe | Current supply not confirmed |
Sources: Sections 3 to 5.
1. Introduction
European product information identifies male hypogonadism, confirmed by clinical features and biochemical testing, as the indication for testosterone replacement. Symptoms alone are insufficient to diagnose testosterone deficiency. Restoring testosterone concentrations in healthy older men solely because levels decline with age is not an authorized use in the EU (EMA n.d.-b).
Treatment selection depends on the patient’s clinical circumstances, preferences and ability to follow the administration instructions. Daily gels allow relatively prompt dose adjustment but require precautions against transfer to other people. Long-acting injections reduce administration frequency but prolong exposure after each dose.
Prescribing in Europe also requires country-specific verification, because brand names, marketing authorization holders, indications and commercial availability differ between countries.
2. Regulatory definitions and terminology
| Term | Meaning |
|---|---|
| Marketing authorization | Permission to market a specified medicinal product under defined conditions |
| National authorization | Authorization granted by a national medicines authority |
| Mutual-recognition or decentralized procedure | Coordinated assessment that leads to national authorizations in the participating countries |
| Centralized authorization | European Commission authorization following EMA scientific assessment, valid in all EU Member States |
| Currently marketed | Commercially supplied; holding an authorization does not guarantee supply |
| Withdrawn authorization | A license that is no longer valid |
| Off-label use | Use outside the authorized product information |
| PSUSA | Periodic safety update report single assessment; EMA publishes the list of nationally authorized products included in each assessment |
Regulatory documents serve different purposes. A public assessment report explains the evaluation that led to an approval. A national register records the status of a particular license. Approved product information describes authorized use. A safety-review product list is an inventory of authorized products at that time and is not an approval announcement.
2.1 Formulations and preparations
A formulation describes composition and delivery, for example testosterone gel 16.2 mg/g or testosterone undecanoate 1,000 mg/4 mL injection.
A preparation is the medicinal product supplied for clinical use, including its formulation, presentation and brand name.
Matching hormone names or percentage concentrations does not make 2 products interchangeable. Different esters have different release characteristics, and different gel pumps deliver different quantities of testosterone per actuation.
3. Comparison of European testosterone formulations
| Preparation | Strength and administration | Advantages | Limitations |
|---|---|---|---|
| Nebido (Grünenthal; historically Bayer) | Undecanoate 1,000 mg/4 mL; deep IM; maintenance every 10 to 14 weeks | Infrequent administration; no risk of secondary transfer | Pulmonary oil microembolism and anaphylactic reactions; observation during and immediately after each injection; exposure cannot be reduced quickly |
| Testosterone EVER Pharma (undecanoate) | 1,000 mg/4 mL; IM | Additional long-acting undecanoate preparation, authorized in Malta in 2025 | National availability and instructions require verification |
| Androtardyl (ADVANZ Pharma) | Enanthate 250 mg/1 mL; IM | Established injectable option; no daily application | Injection discomfort; peak and trough fluctuation |
| Testoviron-Depot-250 (Jenapharm) | Enanthate 250 mg/1 mL (180 mg testosterone); IM | German enanthate preparation | Peak and trough fluctuation; German product information applies |
| Testosterone DESMA and Testosterone EVER Pharma (enanthate) | 250 mg/1 mL; listed in the French enanthate generic group | Additional national enanthate preparations | The company name alone does not identify the ester |
| Testosterone Enanthate/Norma | 250 mg/mL; IM | Enanthate preparation authorized in Malta in 2026 | Country-specific supply and prescribing conditions |
| Testex Prolongatum (Desma) | Cypionate 100 mg/2 mL or 250 mg/2 mL; IM every 2 to 4 weeks | Adjustable schedule; no risk of secondary transfer | Peak and trough variation; repeated injections |
| Sustanon 250 (Aspen) | Per mL: propionate 30 mg, phenylpropionate 60 mg, isocaproate 60 mg and decanoate 100 mg (250 mg total esters); deep IM | No daily administration | Mixed esters do not prevent fluctuation; formulated in arachis oil |
| Omnadren 250 (Bausch Health) | Same 4-ester composition per mL as Sustanon 250; IM | Mixed-ester alternative authorized in Poland | Product-specific dosing; excipients include arachis oil and benzyl alcohol |
Sources: (Grünenthal n.d.; Malta Medicines Authority n.d.-c; BDPM n.d.-a; Jenapharm 2025; BDPM n.d.-b; BDPM n.d.-d; Malta Medicines Authority n.d.-b; Desma n.d.; Aspen n.d.; Bausch Health n.d.).
Strengths require careful interpretation. Testex 250 mg/2 mL contains 125 mg/mL, whereas enanthate 250 mg/1 mL contains 250 mg/mL. Ester mass also differs from testosterone content: 250 mg of testosterone enanthate corresponds to 180 mg of testosterone (BDPM n.d.-d; Jenapharm 2025), and 1,000 mg of testosterone undecanoate corresponds to 631.5 mg of testosterone (BDPM n.d.-c).
Under the Nebido product information, 1,000 mg is injected every 10 to 14 weeks, and the first interval may be shortened to a minimum of 6 weeks (Grünenthal n.d.). The US undecanoate product Aveed uses a different strength and schedule: 750 mg (3 mL) at initiation, a second injection after 4 weeks and then 1 injection every 10 weeks, with 30 minutes of observation in a healthcare setting after each injection under a restricted distribution program (FDA 2014). The 2 regimens are not interchangeable.
| Preparation | Formulation and presentation | Advantages | Limitations |
|---|---|---|---|
| Testogel 50 mg sachet (Besins) | 1% gel (10 mg/g); 50 mg testosterone in 5 g; starting dose 5 g once daily | Noninvasive; established sachet presentation | Transfer risk; dose steps limited to sachet sizes |
| Testogel 16.2 mg/g / Androgel (Besins) | Pump delivers 20.25 mg per actuation; 40.5 mg sachets (2.5 g) also authorized | Noninvasive; metered dose adjustment | Transfer risk; variable absorption; daily adherence |
| Androtop (Besins) | Name used in Poland and Slovenia for the 16.2 mg/g product family | Established transdermal delivery | Presentation must be checked locally |
| Androtopic (historical Finnish name) | 16.2 mg/g gel | Historical regional preparation | Finnish authorization canceled in June 2023 |
| Tostran (ADVANZ Pharma) | 20 mg/g; 10 mg per actuation | Smaller dose increments | Skin reactions; transfer precautions |
| Testavan / Testarzon (Simple Pharma; Androlabs holds Testarzon in Ireland) | 20 mg/g; 23 mg per actuation; applicator | Application without the hands | Transfer risk remains; application site affects absorption |
| Testotop (Dr. August Wolff) | 25 mg/g; 62.5 mg and 125 mg sachets | Additional gel concentration | Nominal doses cannot be directly substituted |
| Testim (historical Irish entry) | 1% gel; 50 mg presentation | Noninvasive delivery | Irish license withdrawn in December 2023 |
Sources: (Laboratoires Besins International 2025; Besins Healthcare n.d.-a; Besins Healthcare n.d.-b; CBG-MEB n.d.-d; Fimea 2023; ADVANZ Pharma n.d.; HPRA n.d.-g; Simple Pharma n.d.; HPRA n.d.-b; Dr. August Wolff 2025; EMA 2026; HPRA n.d.-c).
Doses per actuation are not interchangeable: Tostran delivers 10 mg per actuation, Testavan 23 mg and Testogel 16.2 mg/g 20.25 mg.
Monitoring schedules also differ. For Testogel 50 mg sachets, serum testosterone is measured in the morning before application, starting from day 3 of treatment (Laboratoires Besins International 2025). Testogel 16.2 mg/g is titrated on pre-dose morning concentrations (Besins Healthcare n.d.-a). For Testavan, serum testosterone is measured 2 to 4 hours after application, approximately 14 and 35 days after starting treatment or after a dose change (Simple Pharma n.d.).
| Preparation | Formulation | Regulatory context | Principal considerations |
|---|---|---|---|
| Andriol / Andriol Testocaps and national equivalents | Undecanoate 40 mg soft capsules | The 2016 EMA product list includes Andriol (for example Austria, Denmark, Hungary, Italy, the Netherlands and Norway), Andriol-T (Portugal), Testocaps (Belgium, Luxembourg), Undestor (Czech Republic, Poland, Romania, Slovakia, Sweden) and Pantestone (France); current national status requires verification | Oral administration; absorption depends on food; divided daily dosing |
| Restandol Testocaps | Undecanoate 40 mg soft capsules | Irish authorization withdrawn on December 31, 2020; also listed for Greece and the UK in 2016 | Historical oral option; not marketed under the Irish license |
Sources: (EMA 2016; HPRA n.d.-a).
Product information for the 40 mg capsule states that it must be taken with a meal to ensure absorption, with half of the daily dose in the morning and half in the evening. The initial dose is usually 120 to 160 mg daily for 2 to 3 weeks, followed by 40 to 120 mg daily according to clinical response (MSD Ireland 2020). This regimen cannot be substituted for the dosing of the newer US oral undecanoate products.
Methyltestosterone is a chemically modified androgen and is outside this review of testosterone and testosterone esters.
| Preparation or category | European evidence | Main characteristics |
|---|---|---|
| Striant SR (Ardana Bioscience) | Historical Irish product information for 30 mg mucoadhesive buccal tablets | Twice-daily application to the gum |
| Testosterone Implant 100 mg | Listed as authorized in Malta in a 2014 regulatory circular | Prolonged release after implantation |
| Testopatch (Pierre Fabre) | 1.2, 1.8 and 2.4 mg/24 h patches listed for France, Germany, Greece, Portugal and Spain in Annex I to the 2014 Article 31 referral; current status requires verification | Continuous delivery; skin and adhesive tolerability |
| Intrinsa | Central EU authorization granted in 2006; withdrawn in 2012 | Historical patch for hypoactive sexual desire disorder (HSDD) in women after surgical menopause |
Sources: (Ardana Bioscience 2009; Malta Medicines Authority 2014; EMA n.d.-c; EMA n.d.-a; European Commission n.d.).
Historical documentation is not evidence of current supply. US approval, importation and compounding do not constitute a European marketing authorization.
4. Regulatory records and approval links
The tables below link each named preparation to an official regulatory record or to the holder’s product information. Original approval announcements were not available for every product; the type of document and its limits are stated for each entry. Dates refer to the stated national record or procedure. Assessment report publication dates, national approval dates and commercial launch dates are different events.
| Product | Authorization evidence | Source |
|---|---|---|
| Nebido | Malta MA1520/00101, September 2, 2005; France January 21, 2005, mutual-recognition procedure | Malta Medicines Authority n.d.-a; BDPM n.d.-c |
| Testosterone EVER Pharma undecanoate 1,000 mg/4 mL | Malta AA1411/09401, January 21, 2025 | Malta Medicines Authority n.d.-c |
| Androtardyl | France, national procedure, June 7, 1996; valid | BDPM n.d.-a |
| Testoviron-Depot-250 | Germany 6929279.00.00; product information dated May 2025; listed in the 2016 EMA product list | Jenapharm 2025; EMA 2016 |
| Testosterone DESMA enanthate | France, decentralized procedure, August 21, 2024; valid | BDPM n.d.-d |
| Testosterone EVER Pharma enanthate 250 mg/1 mL | Listed in the French enanthate generic group; product-specific record not reviewed | BDPM n.d.-b |
| Testosterone Enanthate/Norma | Malta MA1025/01302, July 13, 2026 | Malta Medicines Authority n.d.-b |
| Testex Prolongatum 100 mg/2 mL | Spain 61.865 | Desma n.d. |
| Testex Prolongatum 250 mg/2 mL | Spain 27.691 | Desma n.d. |
| Sustanon 250 | Lithuania LT/1/97/1261/003, authorized June 6, 1997 and renewed August 12, 2008; UK status recorded separately | SMCA n.d.; MHRA n.d. |
| Omnadren 250 | Polish approved product information: composition and indications | Bausch Health n.d. |
| Product | Authorization evidence | Source |
|---|---|---|
| Testogel 50 mg sachets | Ireland PA1054/002/002, June 3, 2003; Netherlands RVG 27724, August 21, 2002; Germany 54563.00.00 | HPRA n.d.-f; CBG-MEB n.d.-a; Besins Healthcare Germany 2024a |
| Testogel 16.2 mg/g | Ireland PA1054/002/004, December 11, 2015; Dutch procedure NL/H/3735/003/DC finalized May 18, 2021; Germany (Testogel Dosiergel) 93105.00.00 | HPRA n.d.-d; CBG-MEB n.d.-c; Besins Healthcare Germany 2024b |
| Testogel 40.5 mg sachets | Dutch procedure NL/H/3735/004/DC finalized June 1, 2021; Ireland PA1054/002/005, July 29, 2022; Germany 7000047.00.00 | CBG-MEB n.d.-d; HPRA n.d.-e; Besins Healthcare Germany 2024c |
| Androgel | National licenses in several Member States under procedure NL/H/3240; not a central EU authorization | EMA 2026 |
| Androtop | Poland 23380; procedure NL/H/3240/001 | EMA 2026 |
| Androtopic 16.2 mg/g | Finnish authorization canceled in June 2023 | Fimea 2023 |
| Tostran | Ireland PA23450/002/001, August 4, 2006; Germany 64953.00.00 | HPRA n.d.-g; ADVANZ Pharma 2025 |
| Testavan | Dutch procedure NL/H/3958/001/DC finalized February 15, 2018; Germany 99264.00.00 | CBG-MEB n.d.-b; CBG-MEB 2019; Simple Pharma 2023 |
| Testarzon | Ireland PA25692/001/001, April 13, 2018; holder Androlabs | HPRA n.d.-b |
| Testotop | Germany 63540.00.00 and 63541.00.00 | EMA 2026; Dr. August Wolff 2025 |
| Testim | Ireland PA2311/001/001, issued April 22, 2005; withdrawn December 21, 2023 | HPRA n.d.-c |
| Product | Authorization evidence | Source |
|---|---|---|
| Andriol / Testocaps family | Listed in the 2016 EMA product list and in Annex I to the 2014 Article 31 referral; not proof of current availability of every presentation | EMA 2016; EMA n.d.-c |
| Restandol Testocaps | Ireland PA1286/054/001, issued November 24, 1978; withdrawn December 31, 2020 | HPRA n.d.-a; MSD Ireland 2020 |
| Striant SR | Ireland PA1228/001/001 (historical product information); current supply not confirmed | Ardana Bioscience 2009 |
| Testosterone Implant 100 mg | Malta AA045/00701, listed in a circular dated October 15, 2014 | Malta Medicines Authority 2014 |
| Testopatch | Listed for France, Germany, Greece, Portugal and Spain in Annex I to the 2014 Article 31 referral | EMA n.d.-c |
| Intrinsa | EU/1/06/352; Commission Decision July 28, 2006; withdrawal May 25, 2012 | EMA n.d.-a; European Commission n.d. |
5. Comparative pharmacokinetics
| Formulation | Administration pattern | Exposure and adjustment |
|---|---|---|
| IM cypionate | Testex: every 2 to 4 weeks | Rise after injection followed by decline; the depot persists after administration |
| IM enanthate | Product-specific repeated injections | Intermittent depot exposure; later doses can be adjusted |
| Mixed esters | Product-specific intervals | Different release rates; fluctuation remains |
| IM undecanoate | Nebido: every 10 to 14 weeks after initiation | Prolonged release; dose cannot be adjusted quickly |
| Gels | Daily | Individual absorption varies; dose changes alter exposure more promptly |
| Oral undecanoate | Divided daily doses with meals | Food intake and formulation influence absorption |
| Buccal tablets | Historical Striant: twice daily | Absorption through the oral mucosa; the tablet can be removed |
| Implants | Prolonged interval | Sustained release; difficult to adjust after insertion |
This comparison summarizes product information and does not establish equivalent doses. Sources: (Desma n.d.; Grünenthal n.d.; Besins Healthcare n.d.-a; MSD Ireland 2020; Ardana Bioscience 2009).
6. Comparative safety and tolerability
6.1 Erythrocytosis
Testosterone can increase hemoglobin and hematocrit. A network meta-analysis of 29 placebo-controlled randomized trials involving 3,393 men found statistically significant mean hematocrit increases with every formulation evaluated: gel 3.0%, oral undecanoate 4.3%, patch 1.4%, IM enanthate or cypionate 4.0% and IM undecanoate 1.6% (Nackeeran et al. 2022).
IM enanthate or cypionate produced a larger increase than patches, and no other difference between formulations reached statistical significance (Nackeeran et al. 2022). These results do not provide a safety ranking for individual European preparations. Product information requires regular monitoring of hemoglobin and hematocrit during long-term therapy (Besins Healthcare n.d.-a; Grünenthal n.d.).
6.2 Cardiovascular safety
The TRAVERSE trial randomized 5,246 men aged 45 to 80 years with hypogonadism and preexisting cardiovascular disease or high cardiovascular risk to 1.62% testosterone gel or placebo gel. The primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 7.0% and 7.3% of patients, respectively (hazard ratio 0.96; 95% CI 0.78 to 1.17), which met the prespecified noninferiority criterion (Lincoff et al. 2023).
Atrial fibrillation, acute kidney injury and pulmonary embolism occurred more frequently in the testosterone group (Lincoff et al. 2023). The trial studied a gel only, and its results cannot be applied automatically to other formulations or patient populations.
6.3 Fertility
Exogenous testosterone suppresses spermatogenesis, and product information states that this suppression may be reversible (Besins Healthcare n.d.-a). Changing the route of administration does not preserve fertility. Fertility plans should therefore be discussed before treatment starts.
6.4 Contraindications and excipients
The product information reviewed here shares contraindications in known or suspected carcinoma of the prostate or breast (Besins Healthcare n.d.-a; Grünenthal n.d.; MSD Ireland 2020). Product-specific contraindications include past or present liver tumors for Nebido (Grünenthal n.d.), and hypercalcemia, hypercalciuria, nephrotic syndrome, ischemic heart disease, untreated congestive heart failure and peanut or soy allergy for Restandol Testocaps (MSD Ireland 2020). Sustanon 250 and Omnadren 250 are formulated in arachis oil, so excipient information should be checked in patients with peanut allergy (Aspen n.d.; Bausch Health n.d.).
6.5 Route-specific tolerability
| Route | Principal concerns |
|---|---|
| Injectable depots | Injection reactions; persistent exposure after a dose |
| Oily injections | Product-specific precautions for pulmonary oil microembolism |
| Gels | Secondary transfer; skin irritation; variable absorption |
| Oral capsules | Requirement to take with food; repeated daily dosing |
| Buccal systems | Local discomfort and difficulty with application |
| Implants | Insertion procedure; dose cannot be reversed easily |
Gel precautions include correct application, handwashing if the gel touches the hands, covering the application site with clothing once the gel has dried, and showering before expected skin contact with another person. An applicator reduces but does not remove the risk of transfer (Simple Pharma n.d.).
7. Clinical selection of testosterone formulations
| Priority | Options to assess | Qualification |
|---|---|---|
| Avoid injections | Authorized gel; locally available oral preparation | Administration and adherence requirements remain |
| Reduce dosing frequency | Long-acting IM undecanoate | Exposure cannot be reduced quickly |
| Avoid topical transfer | Appropriate non-topical preparation | Other route-specific risks remain |
| Allow prompt dose adjustment | Daily gel | Correct sampling and titration required |
| Avoid dosing with meals | Suitable non-oral preparation | Consider the alternative administration requirements |
| Fluctuating symptoms | Review dose, interval and route | Symptoms alone do not confirm inadequate exposure |
| Minimize cost | Compare locally authorized products and reimbursement | No reliable Europe-wide price ranking |
| Preserve fertility | Specialist assessment before treatment | Changing the testosterone formulation does not preserve fertility |
These are practical selection considerations, not a ranking of products. Treatment should follow the authorized indication, clinical response, laboratory findings, tolerability and patient preferences.
8. Testosterone formulations in women
Intrinsa received a central EU authorization in 2006 for HSDD in women who had undergone bilateral oophorectomy and hysterectomy (surgically induced menopause) and were receiving concomitant estrogen therapy. The authorization was withdrawn in 2012 at the holder’s request for commercial reasons (EMA n.d.-a; European Commission n.d.).
Some national labels contain other female indications. The Polish Omnadren 250 product information describes exceptional use in women with conditions associated with hyperestrogenism (Bausch Health n.d.). This label does not authorize use for HSDD or for routine menopausal treatment.
The International Society for the Study of Women’s Sexual Health (ISSWSH) guideline recommends systemic transdermal testosterone for appropriately assessed women with HSDD. Government-approved male transdermal formulations can be used cautiously at doses appropriate for women, with monitoring for androgen excess and of total testosterone concentrations. Long-term safety has not been established, and compounded products are not recommended (Parish et al. 2021).
In the UK, NICE guideline NG23 recommends considering testosterone supplementation for people with low sexual desire associated with menopause if hormone replacement therapy (HRT) alone is not effective. NICE notes that this was an off-label use of testosterone when the recommendation was made in November 2015 (NICE 2015).
This review identified no current European marketing authorization for a testosterone product in HSDD in women. Use of male transdermal formulations in women is therefore off-label. Clinical recommendations and marketing authorization are separate matters, and the jurisdiction and product license must be checked before a preparation is described as approved for women.
9. Conclusions
European testosterone preparations include several injectable esters, mixed-ester injections, gels and established oral undecanoate capsules. Buccal tablets, implants and patches are part of the regulatory history.
The clinically relevant differences between them concern exposure, administration burden, transfer precautions, tolerability and dose adjustment. Nominal testosterone strength alone does not determine equivalence.
An accurate regulatory description links each product to a jurisdiction, a formulation and a license status. Authorization, commercial availability, historical use and importation describe different circumstances.
References
Web sources were accessed on November 10, 2026. “n.d.” indicates a regulatory database record or web page without a publication date.
ADVANZ Pharma (2025). Tostran 20 mg/g transdermales Gel: Fachinformation (Zulassungsnummer 64953.00.00), Stand July 2025. Fachinfo-Service.
Ardana Bioscience (2009). Striant SR 30 mg mucoadhesive buccal tablets: summary of product characteristics (PA1228/001/001). Health Products Regulatory Authority.
Besins Healthcare Germany (2024a). Testogel 50 mg transdermales Gel im Beutel: Fachinformation (Zulassungsnummer 54563.00.00), Stand November 2024. Fachinfo-Service.
Besins Healthcare Germany (2024b). Testogel Dosiergel 16,2 mg/g Gel: Fachinformation (Zulassungsnummer 93105.00.00), Stand November 2024. Fachinfo-Service.
Besins Healthcare Germany (2024c). Testogel 40,5 mg transdermales Gel im Beutel: Fachinformation (Zulassungsnummer 7000047.00.00), Stand November 2024. Fachinfo-Service.
CBG-MEB (2019). Public assessment report, summary: Testavan 20 mg/g gel voor transdermaal gebruik (NL/H/3958/001/DC). Medicines Evaluation Board, Netherlands (CBG-MEB).
Dr. August Wolff (2025). Testotop Gel 62,5 mg and 125 mg: Fachinformation, Stand July 2025. Copy of the holder’s product information hosted by Mediately.
EMA (2016). Testosterone (all formulations apart from topical use and testosterone undecanoate injection): list of nationally authorised medicinal products, PSUSA/00002907/201512 (EMA/730861/2016). European Medicines Agency.
EMA (2026). Testosterone (topical use): list of nationally authorised medicinal products, PSUSA/00002908/202412. European Medicines Agency.
EMA (n.d.-a). Intrinsa: EPAR (withdrawn). European Medicines Agency.
EMA (n.d.-b). Testosterone-containing medicines: Article 31 referral. European Medicines Agency.
FDA (2014). Aveed (testosterone undecanoate) injection: prescribing information. US Food and Drug Administration.
Fimea (2023). Granted and cancelled marketing authorisations, June 2023. Finnish Medicines Agency.
Jenapharm (2025). Testoviron-Depot-250: Fachinformation (Zulassungsnummer 6929279.00.00), Stand May 2025. Fachinfo-Service.
Laboratoires Besins International (2025). Testogel 50 mg transdermal gel in sachet: summary of product characteristics (PA1054/002/002). Health Products Regulatory Authority.
Lincoff AM, Bhasin S, Flevaris P, et al. (2023). Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 389(2):107-117. PMID
Malta Medicines Authority (2014). Circular P25/2014: PRAC review does not confirm increase in heart problems with testosterone medicines.
Malta Medicines Authority (n.d.-a). Nebido 1000 mg/4 mL solution for injection (MA1520/00101).
MSD Ireland (2020). Restandol Testocaps 40 mg soft capsules: summary of product characteristics. Health Products Regulatory Authority.
Nackeeran S, Kohn T, Gonzalez D, et al. (2022). The effect of route of testosterone on changes in hematocrit: a systematic review and Bayesian network meta-analysis of randomized trials. J Urol 207(1):44-51. PMID
Parish SJ, Simon JA, Davis SR, et al. (2021). International Society for the Study of Women’s Sexual Health clinical practice guideline for the use of systemic testosterone for hypoactive sexual desire disorder in women. J Sex Med 18(5):849-867. PMID
Simple Pharma Company (2023). Testavan 20 mg/g transdermales Gel: Fachinformation (Zulassungsnummer 99264.00.00), Stand August 2023. Fachinfo-Service.